A sensitive and kinetically defined radiochemical assay for canine and human serum thymidine kinase 1 (TK1) to monitor canine malignant lymphoma

Sharif, Hanan; Euler, Henrik von; Westberg, Sara; He, Ellen; Wang, L.; Eriksson, Staffan

doi:10.1016/j.tvjl.2012.03.006

Cited by 21 publications

(36 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The TK1 activity in serum samples was determined by using an optimized 3 [H]-dThd phosphorylation assay as described previously [24, 28]. In brief, 10 μl of serum sample was incubated with a reaction buffer containing 20 mM Tris/HCl, pH 7.6, 2 mM dithiothreitol, 5 mM NaF, 5 mM MgCl 2 , 5 mM ATP, and 5 μM of dThd at 37 °C for 1 h. Then 10 μl was applied on DE-81 filter paper (Whatman).…”

Section: Methodsmentioning

confidence: 99%

“…The results were obtained with clinical samples from breast cancer patients with known TNM staging as well as CA 15-3 levels. The same samples were analyzed with TK 210 ELISA and TK1 activity assay [24, 28]. The TK 210 ELISA appears to offer many advantages such as elimination of radioactive materials, easily performed in clinical chemistry laboratories, and a capacity to detect early stage breast cancer disease.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A clinical evaluation of the TK 210 ELISA in sera from breast cancer patients demonstrates high sensitivity and specificity in all stages of disease

Kumar

Aronsson²,

Pilko

et al. 2016

Tumor Biol.

Self Cite

View full text Add to dashboard Cite

Thymidine kinase (TK1) is an enzyme involved in DNA synthesis that leaks into the blood as a result of high cell turnover, particularly in the case of cancer. Serum TK1 activity has been used for prognosis and monitoring of leukemia and lymphoma patients for many years. Here, we describe the first clinical results with the newly developed TK 210 ELISA from AroCell AB. Sera from 124 breast cancer patients with known TNM classification along with sera from 53 healthy females were analyzed by TK 210 ELISA for TK1 protein and TK1 activity levels by the 3[H]-deoxythymidine (dThd) phosphorylation assay. The limit of detection for the TK 210 ELISA was 0.17 ng/ml, and 60 % of the sera from female blood donors were below this value. The median TK1 levels found in sera from breast cancer patients with T1 to T4 stage disease were 0.31, 0.46, 0.47, and 0.55 ng/ml, and these levels significantly differed from healthy controls. The median values of the biomarker CA 15-3 were also increased in patient sera from T1 to T4 patients (16, 34, 36, 40 U/ml, respectively). TK 210 ELISA showed significantly higher sensitivity for the T1 and T2 breast cancer patients compared to the TK activity assay. The combination of the TK1 ELISA and CA 15-3 biomarkers demonstrated a significant increase in sensitivity up to 15 % compared to each marker alone. This evaluation of the TK 210 ELISA strongly suggests that it can provide independent and complementary information for patients with breast cancer.Electronic supplementary materialThe online version of this article (doi:10.1007/s13277-016-5024-z) contains supplementary material, which is available to authorized users.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A clinical evaluation of the TK 210 ELISA in sera from breast cancer patients demonstrates high sensitivity and specificity in all stages of disease

Kumar

Aronsson²,

Pilko

et al. 2016

Tumor Biol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…[2][3][4] TK1 expression is limited to proliferating cells, and hematopoietic malignancies have very high cell proliferation rates. [2][3][4][5] In human oncology, serum TK1 levels provide information on prognosis and treatment efficacy in leukemia, multiple myeloma, and Hodgkin and non-Hodgkin lymphoma. 2,4,5 In veterinary species, high levels of serum TK1 compared with normal range are detected in canine lymphoma, splenic hemangiosarcoma, and feline lymphoma.…”

Section: Tests For Lymphoma Veterinary Diagnostics Institute Tkcanine1mentioning

confidence: 99%

“…[2][3][4][5] In human oncology, serum TK1 levels provide information on prognosis and treatment efficacy in leukemia, multiple myeloma, and Hodgkin and non-Hodgkin lymphoma. 2,4,5 In veterinary species, high levels of serum TK1 compared with normal range are detected in canine lymphoma, splenic hemangiosarcoma, and feline lymphoma. [2][3][4][5][6][7][8] Solid tumors in dogs and humans do not show consistently increased levels precluding serum TK1 levels as a general biomarker for all cancer histologies.…”

Section: Tests For Lymphoma Veterinary Diagnostics Institute Tkcanine1mentioning

confidence: 99%

“…2,4,5 In veterinary species, high levels of serum TK1 compared with normal range are detected in canine lymphoma, splenic hemangiosarcoma, and feline lymphoma. [2][3][4][5][6][7][8] Solid tumors in dogs and humans do not show consistently increased levels precluding serum TK1 levels as a general biomarker for all cancer histologies. 3 However, it is used in humans for breast, lung, and colorectal cancer.…”

Section: Tests For Lymphoma Veterinary Diagnostics Institute Tkcanine1mentioning

confidence: 99%

See 1 more Smart Citation

Cancer Screening Tests for Small Animals

Schleis

2014

Veterinary Clinics of North America: Small Animal Practice

View full text Add to dashboard Cite

Twenty Years of Research on 3‐Carboranyl Thymidine Analogs (3CTAs)

Tjarks

2018

Boron‐Based Compounds

View full text Add to dashboard Cite

A sensitive and kinetically defined radiochemical assay for canine and human serum thymidine kinase 1 (TK1) to monitor canine malignant lymphoma

Cited by 21 publications

References 25 publications

A clinical evaluation of the TK 210 ELISA in sera from breast cancer patients demonstrates high sensitivity and specificity in all stages of disease

A clinical evaluation of the TK 210 ELISA in sera from breast cancer patients demonstrates high sensitivity and specificity in all stages of disease

Cancer Screening Tests for Small Animals

Twenty Years of Research on 3‐Carboranyl Thymidine Analogs (3CTAs)

Contact Info

Product

Resources

About